Eagle Pharmaceuticals granted J-Code and pass-through status for Barhemsys

Eagle Pharmaceuticals announced that Centers for Medicare & Medicaid Services – CMS – has established a unique, product-specific billing code and granted transitional pass-through payment status for Barhemsys injection. The new Healthcare Common Procedure Coding System – HCPCS – Level II code – J-code – and will be effective on January 1, 2024, replacing the C-code which will be discontinued. Beginning October 1, Barhemsys became eligible for separate reimbursement outside of the surgical bundled payment in both the ambulatory surgery center and hospital outpatient department care settings. J-codes are reimbursement codes intended to simplify the claims submission and documentation process, facilitating access for patients. Transitional pass-through payments provide additional payment for new devices, drugs, and biologicals that meet eligibility criteria for a period of at least two years but not more than three years. The granting of pass-through status helps streamline the reimbursement process and facilitates patient access to Barhemsys.